Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media
Strategic Communication and Public Relations

Algorithm identifies cancer drivers

No. 01c2 | 10/01/2022 | by Koh

Genetic alterations that promote the development and spread of tumors are difficult to identify. This is especially true for mutations in the non-protein-coding regions of the genome, which include all important regulatory sequences. Scientists at the German Cancer Research Center have now published an algorithm that detects cancer drivers in both the protein-coding and non-coding regions of the genome.

© Adobe Stock

Accumulations of mutations in a cell cause cancer to develop and spread. However, only a small proportion of the mutations identified in a patient are responsible for a cell becoming malignant. Such so-called driver mutations give the cells a selective advantage that can cause them to multiply more quickly.

One of the greatest difficulties in cancer research is to determine whether the mutation is a cancer-driving mutation or just a neutral "passenger mutation" that has no effect on the disease. To make this distinction, researchers examine whether the mutation in question is significantly more common in the cancer genome than in the genome of healthy individuals.

"In the protein-coding part of the genome, which makes up only about two percent of the total genome, this works to some extent. But when we look for driver mutations in the non -coding regions, which include all the important regulatory sequences, this method reaches its limits," says Marc Zapatka of the German Cancer Research Center. This is because DNA damage does not occur at all positions of the genome equally and with equal probability. Moreover, very little is known about the consequences of mutations in this part of the genome.

Zapatka and colleagues have now taken a different approach: They have developed an algorithm that examines such mutations that lie within so-called mutational signatures. Scientists use this term to describe the various characteristic traces left in the genome by mutagenic events such as environmental factors (i. e. UV radiation), faulty DNA repair or misdirected enzyme activity. "We know that many of the cancer-driving mutations known today lie within such mutational signatures. Therefore, it seemed promising to us to specifically take a closer look at these areas," Zapatka explains the background.

With the help of the "sigDriver" algorithm, the genome of large cancer cohorts can be searched for mutations in the coding as well as in the non-coding region.

The DKFZ researchers used sigDriver to analyze the genomes of a total of 3813 tumors whose entire genomes had been sequenced as part of the International Cancer Genome Consortium (ICGC), The Cancer Genome Atlas program, and a study of pediatric tumors.

"We were surprised that despite the new approach, the algorithm identified the majority of already known tumor-driving mutations, even in the non-protein-coding region of the genome, which has rarely been considered in these analyses," comments Zapatka.

However, the analysis also revealed previously unknown but potentially tumor-driving mutation hotspots. The team was able to link 32 mutational hotspots to APOBEC activity, of which only eleven were already known and eleven others are potentially regulatory. The acronym APOBEC refers to an entire family of mRNA-editing enzymes that are part of the innate virus defense system in humans: The enzymes attack the genome of RNA viruses at specific sites - but can also cause mutations in the human genome, resulting in known signatures as traces of this damage.

The newly identified mutations must now be confirmed in larger groups of patients, and the cancer-relevant effects of the mutations must be analyzed in detail and possibly verified experimentally. The Heidelberg team is making sigDriver available to expert colleagues worldwide for this purpose.

"We have already found new tumor-driving mutations that can help identify cancer patients with high-risk tumors. We expect that analyzing larger groups of patients with the same type of cancer with sigDriver will reveal even more cancer drivers, especially in regulatory regions of the genome," study leader Zapatka expects.

John K.L. Wong, Christian Aichmüller, Markus Schulze, Mario Hlevnjak, Shaymaa Elgaafary, Peter Lichter, Marc Zapatka: Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions
Nature Communications 2022, DOI:10.1038/s41467-021-27792-6

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS